Novo Nordisk A/S Common Stock (NVO)

Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the day, following the release of late-stage study results for its highly anticipated oral weight-loss drug, orforglipron. While the drug met its primary

Eli Lilly's obesity drug data misses targets, boosting shares of Novo Nordisk, Viking, Structure, and Terns amid promising trial updates.

An analyst called the unexpected flop a "once-in-a-blue-moon" occasion for Eli Lilly's dominant weight-loss franchise.

Eli Lilly shares fell after orforglipron's Phase 3 data showed less weight loss than rival drugs, despite a strong Q2 earnings beat and raised guidance.

The Danish pharmaceutical company is fighting a competitive war on several fronts.

A surge in private market investment has investors wondering: Is it time to bet bigger on biotech?

Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021.

Competition is hurting sales of critical products.

The company is struggling with several headwinds as it works to develop its obesity plan.

Between battered industries and overlooked opportunities, plenty of dividend-paying companies have slipped.

The company says it's working to ensure patients only receive semaglutide produced by Novo Nordisk.

Novo Nordisk reported Q2 sales of $11.7 billion, missing consensus. Sales increased by 13% in Danish kroner, driven by GLP-1 diabetes and obesity care sales.

Tech entrepreneur Bryan Johnson refutes claims that Novo Nordisk AS's Ozempic demonstrates anti-aging properties.

The results follow Novo’s worst weekly decline in its history after the company slashed its full-year guidance.

The U.S. stock market experienced a turbulent start to August 2025, marked by significant declines for several prominent companies. This downturn, following a volatile end to July, has left investors grappling with mixed signals and heightened uncertainty. While the broader market saw a rebound in early August, driven by

Are you brave enough to catch this falling knife?

Management pointed to competitors gaining market share in key product categories.

UBS downgraded Novo Nordisk to ‘Neutral’ from ‘Buy’ with a price target of DKK 340, down from DKK 600.

Novo Nordisk stock is down over 43% in 2025 as investors weigh weak guidance, GLP-1 competition, and the potential for a rebound after earnings

The company makes implantable devices for sleep apnea, an area Eli Lilly is marketing its weight-loss drug.

Management told investors to expect slower sales and profit growth in 2025.

Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss from a single dose.